UNASSIGNED: Remarkable progress has been achieved in @entity1582 , and @entity1 median survival has been extended 3- to 4-fold. Specifically, there have been 18 newly approved treatments for @entity1582 in the past 12 years, including seven in 2015, and the treatment paradigm and @entity1 outcome have been transformed. The definition of @entity1 benefitting from these therapies has been broadened. Response criteria now include @entity41 ( @entity41 ), assessed in bone marrow by multicolor flow cytometry or sequencing, and by imaging for extramedullary disease. Initial therapy for transplant candidates is a triplet incorporating novel therapies-that is, @entity6985 , @entity1749 , and @entity619 or @entity786 , @entity1749 , and @entity619 . @entity6985 maintenance until progression can prolong progression-free and overall survival in standard-risk @entity1582 , with incorporation of proteasome inhibitor for high-risk disease. Studies are evaluating the value of early versus late transplant and @entity41 as a therapeutic goal to inform therapy. In nontransplant @entity1 , triplet therapies are also preferred, with doublet therapy reserved for frail @entity1 , and maintenance as described above. The availability of second-generation proteasome inhibitors (carfilzomib and @entity34680 ), immunomodulatory drugs ( @entity16291 ), histone deacetylase inhibitors (panobinostat), and monoclonal antibodies (elotuzumab and daratumumab) allows for effective combination therapies of @entity66 as well. Finally, novel therapies targeting protein degradation, restoring autologous memory anti- @entity1582 immunity, and exploiting genetic vulnerabilities show promise to improve @entity1 outcome even further. Clin Cancer Res; 22(22); 5419-27.   2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "MULTIPLE MYELOMA MULTIPLYING THERAPIES".

Progress and Paradigms in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity66 :: ('MESH:D004194', 'Disease') :: ['relapsed disease'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'minimal residual disease'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity16291 :: ('MESH:C467566', 'Chemical') :: ['pomalidomide'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity6985 :: ('MESH:C467567', 'Chemical') :: ['Lenalidomide', 'lenalidomide'] @entity34680 :: ('MESH:C548400', 'Chemical') :: ['ixazomib'] @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib']
@entity1582 :: (MESH:D009101,Disease) :: ['Multiple Myeloma']
